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ABSTRACT
A defining feature of mycobacterial redox metabolism is the use of an unusual deazaflavin cofactor, F420. This cofactor enhances
the persistence of environmental and pathogenic mycobacteria, including after antimicrobial treatment, although the molecular
basis for this remains to be understood. In this work, we explored our hypothesis that F420 enhances persistence by serving as a
cofactor in antimicrobial-detoxifying enzymes. To test this, we performed a series of phenotypic, biochemical, and analytical
chemistry studies in relation to the model soil bacteriumMycobacterium smegmatis. Mutant strains unable to synthesize or re-
duce F420 were found to be more susceptible to a wide range of antibiotic and xenobiotic compounds. Compounds from three
classes of antimicrobial compounds traditionally resisted by mycobacteria inhibited the growth of F420 mutant strains at sub-
nanomolar concentrations, namely, furanocoumarins (e.g., methoxsalen), arylmethanes (e.g., malachite green), and quinone
analogues (e.g., menadione). We demonstrated that promiscuous F420H2-dependent reductases directly reduce these compounds
by a mechanism consistent with hydride transfer. Moreover,M. smegmatis strains unable to make F420H2 lost the capacity to
reduce and detoxify representatives of the furanocoumarin and arylmethane compound classes in whole-cell assays. In contrast,
mutant strains were only slightly more susceptible to clinical antimycobacterials, and this appeared to be due to indirect effects
of F420 loss of function (e.g., redox imbalance) rather than loss of a detoxification system. Together, these data show that F420
enhances antimicrobial resistance in mycobacteria and suggest that one function of the F420H2-dependent reductases is to
broaden the range of natural products that mycobacteria and possibly other environmental actinobacteria can reductively
detoxify.
IMPORTANCE
This study reveals that a unique microbial cofactor, F420, is critical for antimicrobial resistance in the environmental actinobac-
teriumMycobacterium smegmatis. We show that a superfamily of redox enzymes, the F420H2-dependent reductases, can reduce
diverse antimicrobials in vitro and in vivo.M. smegmatis strains unable to make or reduce F420 become sensitive to inhibition by
these antimicrobial compounds. This suggests that mycobacteria have harnessed the unique properties of F420 to reduce struc-
turally diverse antimicrobials as part of the antibiotic arms race. The F420H2-dependent reductases that facilitate this process
represent a new class of antimicrobial-detoxifying enzymes with potential applications in bioremediation and biocatalysis.
The redox cofactor F420 [7,8-didemethyl-8-hydroxy-5-deazari-boflavin-5=-phosphoryllactyl(glutamyl)n glutamate] is unique
to bacteria and archaea. This deazaflavin is structurally similar to
flavin adenine dinucleotide (FAD) and flavin mononucleotide
(FMN) but behaves more similarly electrochemically to the nico-
tinamides NAD and NADP (1). An obligate two-electron carrier,
F420 mediates hydride transfer to or from a wide range of organic
carbon compounds. Its low standard redox potential of340mV
enables it to catalyze otherwise challenging reduction reactions,
for example, those of enone, imine, enamine, and nitro groups
(2–5). Due to these unique properties, F420 has been harnessed by
bacteria and archaea in a wide range of metabolic pathways. The
cofactor is best known for its role in methanogens, where it serves
as the main catabolic cofactor (6). However, we have shown it is
also synthesized by aerobic bacteria from at least three phyla, the
Actinobacteria, Chloroflexi, and Proteobacteria (7). While the co-
factor is of secondary importance to nicotinamides in bacteria, an
increasing number of redox reactions in central and secondary
metabolic pathways have been shown to depend on it (1). These
include the biodegradation of aflatoxins and nitrophenols (2, 4),
the biosynthesis of tetracycline and lincosamide antibiotics (8, 9),
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and the reduction of biliverdin, quinones, and mycolic acids (5,
10, 11). In turn, it was recently recognized that F420 may have a
significant role in shaping the biological and chemical composi-
tions of soil ecosystems (7).
In recent years, F420 has inspired interest for its role in the
redox metabolism of mycobacteria, an actinobacterial genus of
environmental and medical significance. Most of these studies
have focused on the soil saprophyteMycobacterium smegmatis and
the human pathogen Mycobacterium tuberculosis. These studies
have shown that F420 is dispensable for growth but essential for the
survival of antibiotic stress, oxidative stress, and hypoxia, for rea-
sons still incompletely understood (10, 12, 13). In this genus, the
cofactor is synthesized by four known enzymes (FbiC, CofC,
CofD, and CofE) and is reduced by the F420-dependent glucose
6-phosphate dehydrogenase (Fgd) (14). The physiological roles of
the cofactor are elicited by F420H2-dependent reductases that cou-
ple the reoxidation of F420H2 to the reduction of organic com-
pounds (1, 5, 11, 15). Genomic and biochemical studies have
shown that mycobacteria synthesize a multiplicity of F420H2-
dependent reductases from two superfamilies, the flavin/deazaf-
lavin oxidoreductases (FDORs) and the luciferase-like hydride
transferases (LLHTs). The soil organism M. smegmatis encodes
some 31 FDORs and 45 LLHTs that are predicted to bind F420 (1,
5, 15). A smaller number of these proteins are encoded in the
reduced genomes of the human pathogens M. tuberculosis and
Mycobacterium leprae (5, 15).
The recently discovered FDOR superfamily is of particular in-
terest because of its physiological and pharmacological roles in
mycobacteria (1, 5). This diverse family is subdivided into 16 sub-
groups (A1 toA4, AA1 toAA6, andB1 to B6), with genes encoding
the A1 and B1 subgroups in multiple copies in individual myco-
bacterial genomes (2, 5, 16, 17). To date, the physiological role of
just one mycobacterial FDOR has been fully defined, a biliverdin
reductase from the B3 subfamily that reduces the heme oxygen-
ation product biliverdin to the potent antioxidant bilirubin (5,
18). Other subgroups have been implicated in quinone and fatty
acid metabolism (5, 10). Several FDORs of the manifold A1 and
B1 subgroups are also known for their ability to reduce several
medically important exogenous compounds, including furano-
coumarin natural products (e.g., aflatoxins) (2, 16) and clinical
nitroimidazole prodrugs (i.e., delamanid and pretomanid) (19–
21). Our previous structural studies have shown that the F420H2
moiety binds at an amphiphilic conserved F420-binding domain,
whereas the substrate binds in a more variable substrate-binding
pocket (1, 2, 5). The promiscuous FDORs of the A1 subgroups are
able to accommodate a range of substrates in wide pockets
through a combination of hydrophobic and hydrophilic interac-
tions involving conserved aromatic residues. Hydride transfer oc-
curs directly between C-5 of F420H2 to the proximal electrophilic
alkene or imine groups of the substrate (2, 5, 18, 22).
Despite the progress in understanding its biochemical basis, it
remains unclear whether substrate promiscuity in the FDOR su-
perfamily is physiologically significant and, if so, how this promis-
cuity has been shaped by natural selection. We recently proposed
that mycobacteria evolved a multiplicity of promiscuous F420H2-
dependent reductases in order to enhance the range of substrates
which they may biodegrade (1, 5). These enzymes may use elec-
trons derived from the cytosolic reservoir of glucose 6-phosphate
(12) to reductively transform exogenous compounds, leading to
their detoxification and/or biomineralization. To explore this hy-
pothesis, this paper investigates the role of F420H2-dependent re-
ductases in the metabolism of a range of antibiotics and xenobi-
otics. By combining cellular physiology, protein biochemistry,
and analytical chemistry approaches, we resolved that F420 is cru-
cial for the ability of mycobacteria to resist a range of antimicro-
bial compounds and demonstrated that F420H2-dependent
FDORs can likely reductively detoxify some of these compounds.
MATERIALS AND METHODS
Bacterial strains and growth conditions. This study employedMycobac-
terium smegmatis mc2155 (23) and two derivative strains containing dis-
ruptions in the genes fgd and fbiCwith kanamycin resistance cassettes (2).
The strains were grown on LBT (lysogeny broth containing 0.05% Tween
80) and maintained on LBT agar. Kanamycin at 20 g · ml1 was used to
propagate the mutant strains. For all physiological experiments, liquid
cultures (30 ml) were grown to mid-exponential phase (optical density at
600 nm [OD600],0.5) in 125-ml aerated conical flasks in a rotary incu-
bator (200 rpm, 37°C).
Phenotypic experiments. Twenty antimicrobial compounds were
sourced from Sigma-Aldrich and dissolved into 1 M working stocks in
dimethyl sulfoxide (DMSO). The structures of the compounds tested are
shown in Table S1 in the supplemental material. Phenotypic experiments
studied the effect of these compounds on the growth and survival of M.
smegmatis and derivative strains. MICs were determined by a standard
protocol (24) by serially diluting the compounds in 96-well plates and
measuring growth inhibition by OD600 following incubation (400 rpm,
37°C, 12 h). Strain viability following challenge with antimicrobial agents
was measured by challenging mid-exponential-phase cultures with the
compound of interest at a concentration of 5 times the MIC of the wild-
type strain. At regular time intervals, 1-ml cultures were centrifuged
(16,000 g, 1min) and resuspended in 1ml of HBTP (Hartmans de Bont
minimal medium supplemented with 0.05% tyloxapol) (25) two times to
remove the compounds. CFU · ml1 were subsequently counted by spot-
plating serially diluted cultures, as previously described (26). No CFU or
MIC differences were observed for DMSO-only controls. To test the ca-
pacity of strains to grow on compounds as a sole source of carbon, expo-
nential-phase cultures were inoculated to a starting OD600 of 0.005 into
HBTPmedium (25) supplemented with either 1 mM or 10 mM the com-
pounds of interest, and growth was determined by the OD600 following
incubation (200 rpm, 37°C, 24 h). Eight compounds were tested: cou-
marin, methoxsalen, imperatorin, menadione, azure B, malachite green,
crystal violet, and phenol red.
Protein expression and purification. Six F420H2-dependent re-
ductases of the flavin/deazaflavin oxidoreductase (FDOR) super-
family (MSMEG_5998, MSMEG_2027, MSMEG_6325, MSMEG_3380,
MSMEG_0048, and MSMEG_5170 loci) and the F420-reducing glucose
6-phosphate dehydrogenase (Fgd) were recombinantly overexpressed in
Escherichia coli BL21(DE3) and purified by nickel-nitrilotriacetic acid
(Ni-NTA) affinity chromatography, as previously described (2, 5). F420
was extracted, purified, and concentrated from a recombinant F420 over-
expression strain of M. smegmatis mc24517 (27) by a combination of
anion-exchange chromatography, hydrophobic interaction chromatog-
raphy, and rotary evaporation, as previously described (28).
Enzymatic assays. Two assays were optimized to monitor F420H2-
coupled substrate reduction. A high-performance liquid chromatography
(HPLC)-basedmethodmonitored the reduction of substrates bymeasur-
ing changes in their absorbance at max (maximum absorbance wave-
length) or their fluorescence at em max (maximum emission wavelength)
in aerobic vials containing the FDOR of interest, F420, Fgd, and glucose
6-phosphate. The secondmethodmonitored the reoxidation of F420H2 by
the absorbance at 420 nm in anoxic mixtures containing prereduced
F420H2 and one of the FDORs. The rates obtained for the two methods
were similar (see Table S2 in the supplemental material), demonstrating
that rates of F420H2 reoxidation are proportional to those with substrate
reduction. However, the second method proved more reliable and sys-
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tematic, in part because it better discriminated between enzyme-depen-
dent and enzyme-independent F420H2-mediated substrate reduction. Us-
ing this method, we assayed the specific activities of the six purified
FDORs for 20 compounds. All assays were prepared in a nitrogen glove
box and used buffers that were degassed by sonication. F420 was enzymat-
ically reduced overnight with 1 M Fgd and purified by spin filtration
using previously reported methods (5). All reaction mixtures contained
degassed Tris buffer (200mMTris, 0.1% [wt/vol] Triton X-100 [pH 8.0])
sequentially supplemented with 50 M substrate, 25 M F420H2, and,
depending on reactivity, between 100 nM and 1 M the FDOR. Reaction
rates weremonitored by recording the initial linear increase in absorbance
at 420 nm using an Epoch 2 microplate spectrophotometer (BioTek).
Specific activities were calculated by subtracting rates of no-enzyme con-
trols and expressed in nmol · min1 · mol enzyme1, as previously
described (2).
LC-MS analysis. For liquid chromatography-mass spectrometry (LC-
MS) analysis of the FDOR-mediated reactions, 100M standards of mal-
achite green and methoxsalen were prepared in 20 mM Tris buffer (pH
8.0). The mass spectra of their FDOR reaction products were measured
after the addition of 100Mglucose 6-phosphate, 10MF420, 1MFgd,
and 1 M MSMEG_2027, followed by incubation at 37°C for 1 h. An
Agilent 1100 series binary LC equipped with a diode array detector and
in-line time of flight mass spectrometer (LC-MSD TOF) were used, with
mass data obtained by electrospray ionization (ESI) in positive ionmode.
Samples were separated on an Agilent Poroshell 120 EC-C18 column (2.7
m, 2.1 by 100 mm), utilizing a gradient protocol composed of buffer A,
with ammonium formate plus 0.1% formic acid; and buffer B, with ace-
tonitrile plus 0.1% formic acid. The applied gradient was as follows: 10%
buffer B from 0.5 min to 60% buffer B at 6.50 min, and then increased to
90% buffer B at 7 min, at a flow rate of 0.4 ml · min1. The Agilent
MassHunter quantitative analysis software was used to analyze product
formation.
Whole-cell consumption assays. Whole-cell assays measured the
consumption of the antimicrobial compounds malachite green and me-
thoxsalen. Mid-exponential-phase cells grown in LBT were centrifuged
(16,000  g, 10 min) and resuspended in a buffer containing 50 mM
MOPS (pH 7.4), 25 mMNaCl, and 25 mM KCl. The antimicrobial com-
pound of interest was then added to a final concentration of 1/2 the MIC
of the fbiC mutant strain. At regular intervals, samples of 200 l were
centrifuged to remove cells (16,000  g, 5 min), and supernatants were
analyzed via a high-performance liquid chromatography–diode array de-
tection (HPLC-DAD)protocol. The analysis was carried out on anAgilent
1200 series system equipped with autosampler and a Poroshell 120 EC-
C18 2.7-m, 2.1 by 100-mm column. A gradient consisting of buffer A
(ultrapure water plus 0.1% formic acid) and buffer B (acetonitrile plus
0.1% formic acid) was applied as follows: 0 to 1 min 10% buffer B, 1 to 5
min 90% buffer B, 5 to 10 min 10% buffer B, 10 to 12 min 10% buffer B.
Degradation of malachite green (retention time, 7.2 min) and methox-
salen (retention time, 6.9 min) was measured by tracking the loss of ab-
sorbance at 615 nm and 310 nm, respectively. Concentration was calcu-
lated by integrating the area of the absorbance peaks and calibrating with
standards of known concentration.
RESULTS
F420-deficient mutants are hypersusceptible to growth inhibi-
tion by antimicrobial compounds.Wecompared the susceptibil-
ity of wild-type and F420-deficient mutant strains to growth inhi-
bition by 20 antimicrobial agents. Two mutant strains were
employed: one unable to synthesize F420 (fbiC::kanmutant) due to
disruption of the gene encoding the first enzyme in the F420 biosyn-
thesis pathway (FbiC), the other unable to reduce F420 (fgd::kan
mutant) due to disruption of the gene encoding F420-dependent
glucose 6-phosphate dehydrogenase (Fgd). Six of the compounds
were first- and second-line clinical antimycobacterial agents. The
remainders were aminocoumarins/furanocoumarins, quino-
lones/fluoroquinolones, quinone analogues, and arylmethane
compounds containing enone, lactone, or imine functionalities
known to be catalytically compatible with F420H2-dependent re-
ductases (2, 5, 10, 16).
TheMICs for the fgd and fbiCmutantswere lower than those of
the wild type for 18 of the 20 compounds (Table 1). The mutant
strains showed greatly increased susceptibility to four compound
classes usually resisted by mycobacteria: furanocoumarins, qui-
none analogues, arylmethane dyes, and quinolones. Whereas
wild-type strains were only compromised by high concentrations
of these compounds, the mutants were susceptible even at sub-
nanomolar levels. In addition, the mutants exhibited small but
reproducible increases in susceptibility to growth inhibition to the
five first-line clinical antimycobacterials tested. SimilarMICswere
observed for the fgd and fbiC mutants, which is consistent with
FbiC being essential for F420 biosynthesis and Fgd being the main
route for F420 reduction in M. smegmatis (1, 14). The slight in-
crease in susceptibility of the fbiC mutant over the fgd mutant for
three of the compounds suggests that some residual functions of
F420 can be maintained in the absence of Fgd.
CFU measurements confirmed that loss of function of F420
reduces the capacity of M. smegmatis to survive treatment with
representative antimicrobial compounds (Fig. 1). Whereas mala-
chite green proved bacteriostatic to the wild-type strain at high
concentrations, the dye rapidly killed F420 mutant strains. Like-
wise, the bactericidal agentmenadione killed the fbiCmutant and,
to a lesser extent, the fgdmutant strains at higher rates than for the
wild-type strain. At 24 h following administration, we observed
reductions in the survival of the fbiCmutant strain versus the wild
type of 10,000-fold for malachite green and 100-fold for menadi-
one (P 0.001). Despite inhibiting growth of the fbiC mutant at
subnanomolar concentrations (Table 1), the furanocoumarin
methoxsalen proved bacteriostatic to all three strains even at a
high concentration (640 g · ml1). CFU and ODmeasurements
confirmed that wild-type cells resumed growth on LBT medium
following initial growth inhibition (Fig. 1). This suggests that the
strain detoxified the furanocoumarin to sub-MIC levels. The mu-
tant strains also exhibited a modest acceleration in killing follow-
ing administration of the clinical antimycobacterial agent rifam-
pin (see Fig. S1 in the supplemental material).
F420H2-dependent reductases directly reduce antimicrobial
compounds.We hypothesized that the increased susceptibility of
the mutant strains to many of the compounds tested was due to
their inability to detoxify the compounds using F420H2-dependent
reductases. To test this, we recombinantly expressed and purified
six F420H2-dependent FDORs (see Fig. S2 in the supplemental
material) from M. smegmatis. Enzymes were selected to cover a
range of FDOR subgroups while focusing on A1 and B1 enzymes
that have previously been shown to display the greatest substrate
promiscuity (2, 5, 16).We spectroscopically measured the rates of
F420H2-dependent reduction of the compounds, employing an-
aerobic conditions to prevent low-level spontaneous F420H2 re-
oxidation. These enzymes catalyzed the F420H2-dependent reduc-
tion of 10 of the 20 compounds tested (Fig. 2). Consistent with
previous observations on the reactivity of F420H2 (11), several
compounds were additionally reduced by F420H2 in an enzyme-
independent manner (see Fig. S3 in the supplemental material).
FDORs transformed quinone analogues at high rates
(100,000 nmol · min1 · mol enzyme1) and furanocou-
marins at low rates (1,000 nmol · min1 · mol enzyme1). In
Jirapanjawat et al.
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addition, all four arylmethane compounds were also reduced by
F420H2 through both FDOR-facilitated (malachite green and crys-
tal violet) (Fig. 2) and nonenzymatic (azure B, phenol red, and
malachite green) activities (see Fig. S3 in the supplemental mate-
rial). While it is well established that mycobacteria reductively
decolorizemalachite green in an F420-dependentmanner (29), the
enzymatic determinants of this process have remained elusive un-
til now. Two of the six clinical antimycobacterials, namely, rifam-
pin and clofazimine, were also reduced, although at very low
rates of below 100 and 600 nmol · min1 · mol enzyme1,
respectively. All six FDORs tested had some degree of promis-
cuity, although they varied significantly in their substrate
ranges and reaction rates. The A1 enzymes (MSMEG_5998 and
MSMEG_2027) exhibited thewidest substrate range and generally
the highest rates of the enzymes, with MSMEG_2027 having de-
tectable activity with all 10 compounds for which FDOR activity
TABLE 1 Antibiotic susceptibility of F420-deficient mycobacteria
a
Substrate
MIC (g · ml1)
MIC ratio (WT/mutant)bWT fgd::kan fbiC::kan
Quinone analogues
Menadione 32 2 2 16
1,4-Naphthoquinone 32 1 1 32
1,2-Naphthoquinone 32 2 2 16
Furanocoumarins and aminocoumarins
Methoxsalen 64 1 1 64
Angelicin 128 1 1 128
Imperatorin 32 0.5 0.5 64
Novobiocin 0.5 0.5 0.5 1
Arylmethane dyes
Malachite green 64 1 0.5 64, 128
Crystal violet 16 1 0.5 16, 32
Phenol red 8 0.5 0.5 16
Azure B 16 2 2 8
Quinolones and fluoroquinolones
Oxolinic acid 16 0.125 0.125 128
Nalidixic acid 128 1 1 128
Ciprofloxacin 0.25 3.1 102 7.8 103 8
Moxifloxacin 6.3 102 6.3 102 3.1 102 1, 2
Clinical antimycobacterials
Rifampin 4 2 2 2
Ethambutol 0.5 0.13 0.13 4
Isoniazid 32 16 16 2
Pyrazinamide 512 256 256 2
Clofazimine 8 4 4 2
a MICs are shown for exponential-phase wild-type (WT), fgd mutant, and fbiC mutant cultures. MICs were determined by serially diluting antibiotic stocks in 96-well plates and
measuring growth inhibition by the OD600. Five first-line antimycobacterials (rifampin, ethambutol, isoniazid, pyrazinamide, and clofazimine) and 1 second-line antimycobacterial
(moxifloxacin) were tested.
b Cells with two values are the ratios for the fgd::kan mutant and fbiC::kan mutant, respectively.
FIG 1 F420-dependent survival of M. smegmatis following antimicrobial challenge. The wild-type (WT), fgd mutant, and fbiC mutant strains were challenged
with three antimicrobials (menadione, methoxsalen, and malachite green) during mid-exponential growth. The survival of the strains, as determined by CFU,
is shown following administration of antimicrobials at 5 times the MIC of the wild-type strain. Error bars represent standard deviations from the results from
three biological replicates. P values were calculated by comparing CFU counts between wild-type and mutant strains. ***, P 0.001; ns, not significant.
F420-Dependent Antimicrobial Detoxification
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was observed. Members of the B1 subgroup (MSMEG_0048 and
MSMEG_3380) had high activities against quinones and aryl-
methanes but not furanocoumarins, whereas representatives of
the A3 (MSMEG_6325) and B3 (MSMEG_5170) subgroups gen-
erally catalyzed reactions at fractional rates compared to the other
FDORs. This is consistent with our previous studies showingmost
FDOR-A and FDOR-B enzymes can reduce aflatoxins, but at rates
varying by four orders of magnitude (2, 16).
HPLC experiments with selected compounds validated that
substrates were reduced by F420H2-dependent reductases. This oc-
curred at rates similar to that of F420H2 reoxidation, suggesting an
equimolar reaction (see Table S2 in the supplemental material).
LC-MS analysis of two of the compounds, methoxsalen and mal-
achite green, demonstrated the emergence of reduced forms of the
compounds, with [M	H] ions corresponding to a 2-Da increase
in the reaction product spectrum (Fig. 3A and B). This is consis-
tent with direct hydride transfer occurring from the C-5 atom of
F420H2 to the electrophilic double bonds of the substrates (Fig. 3C
andD), coupled with addition of a proton from either solvent or a
proximate residue, as observed for other FDOR-dependent reac-
tions (2, 5, 17, 18, 30). Our previous structural studies provide a
basis for understanding how these substrates can be accommo-
dated into the substrate-binding sites of FDORs through both
hydrophilic and hydrophobic interactions (1, 2, 5, 18). All other
compounds reduced by F420H2 also contain functional groups
known to be reduced by FDORs (1), namely, enones (quinone
analogues), lactones (furanocoumarins), and imines (arylmeth-
ane dyes, clofazimine, and rifampin). On this basis, we propose
probable reaction mechanisms for their reductions in Fig. S4 in
the supplemental material. Two interesting exceptions are the
quinolones (oxolinic acid and nalidixic acid), which were not re-
duced by FDORs despite containing enone moieties and inhibit-
ing the growth of F420 mutant strains. It is possible that these
compounds are instead substrates for other F420H2-dependent en-
zymes, such as the luciferase-like hydride transferases (LLHTs).
F420 is required for detoxification of antimicrobial com-
pounds. With the exception of the quinolones, all compounds
that strongly inhibited growth of F420mutant strains were reduced
by FDORs (see Fig. S5 in the supplemental material). The corre-
lation between the phenotypic and biochemical data suggests that
F420H2-dependent reductases directly detoxify many of these
compounds, and the loss of these activities results in enhanced
growth inhibition. It is impossible to test this hypothesis with
targeted FDOR knockouts, as M. smegmatis encodes multiple
F420H2-dependent reductases with overlapping substrate specific-
ities, including five enzymes each from the promiscuous fast-act-
ing A1 and B1 subgroups. Instead, we substantiated this hypoth-
esis by comparing the abilities of the wild-type andmutant strains
to detoxify model antimicrobial compounds from two distinct
chemical classes that were reduced in vitro by FDORs. The fura-
nocoumarin methoxsalen and the arylmethane malachite green
were selected on the basis that their reduction can be sensitively
monitored via diode array detection when supplemented in cul-
tures at sub-MIC levels.
The wild-type strain transformed the two antimicrobial com-
pounds tested. All the malachite green added was consumed to
below-detectable limits within 40 min, while methoxsalen was
more slowly degraded over 120 h (Fig. 3E and F). In contrast, the
concentrations of the two compounds in the mutant cultures re-
mained similar to those in the no-culture controls (although, in
accordance with previous reports [31], significant culture-inde-
pendent decolorization of malachite green was also observed).
The rates of biotransformation observed suggest that the wild-
type strain may survive malachite green treatment and recover
from methoxsalen-induced growth inhibition (Fig. 1) by reduc-
tively detoxifying these compounds. Malachite green may have
FIG 2 Reduction of antimicrobials by F420H2-dependent reductases from Mycobacterium smegmatis. Six characterized F420H2-dependent reductases
(MSMEG_5998, MSMEG_2027, MSMEG_6325, MSMEG_3380, MSMEG_0048, and MSMEG_5170) were recombinantly expressed and purified from E. coli.
The specific activity for each substrate was determined by recording the rate of F420H2 reoxidation by absorbance at 420 nm. Error bars show standard deviations
from the results from three independent replicates. No F420H2-dependent reduction of ethambutol, isoniazid, pyrazinamide, oxolinic acid, novobiocin, nalidixic
acid, ciprofloxacin, ormoxifloxacinwas observed. Significant rates of enzyme-independent F420H2 reoxidationwere observed for phenol red and azure B (see Fig.
S3 in the supplemental material).
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been transformed more rapidly than methoxsalen in vivo because
FDORs able to reduce the compound are more numerous and
faster acting (Fig. 2). In combination, these results show that phe-
notypic resistance (Fig. 1), in vitro reactivity (Fig. 2), and in vivo
reactivity (Fig. 3) tomethoxsalen andmalachite green are strongly
correlated and F420 dependent.
We previously predicted that F420H2-dependent reductases
might also support growth ofmycobacteria by reductively activat-
ing exogenous compounds for use as sources of carbon and energy
(1, 2, 16). However, we confirmed in vivo that neither wild-type
nor mutant strains could grow when inoculated with minimal
salts medium supplemented with any one of eight known FDOR
FIG 3 F420-dependent antimicrobial detoxification in vitro and in vivo. (A and B) Mass spectra of methoxsalen (A) and malachite green (B) before and after
reduction with the FDOR MSMEG_2027. Major peaks corresponding to oxidized (m/z 217) and reduced (m/z 219) methoxsalen and oxidized (m/z 329) and
reduced (m/z 331)malachite green were observed. For both compounds, there are also ionization fragments corresponding to the demethylated compounds. (C
and D) Plausible mechanisms for FDOR-mediated hydride transfer from F420H2 to methoxsalen (C) and malachite green (D) are shown based on the mass
spectra. (E and F) F420-dependent reduction of methoxsalen (E) and malachite green (F) in resting cells of Mycobacterium smegmatis. The concentration of the
antimicrobial following administration at 1/2 the MIC of the fbiC mutant strain is shown over time for the wild-type strain, fbiC mutant, fgd mutant, and a
no-culture control.
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substrates as the sole carbon or energy source. This is again con-
sistent with our hypothesis that mycobacteria employ F420H2-de-
pendent reductases to support detoxification rather than growth.
DISCUSSION
To summarize, this study makes three interrelated findings. First,
the cofactor F420 is critical for resistance of mycobacteria to anti-
microbial compounds. Strains unable to synthesize or reduce this
cofactor were hypersusceptible tomost antimicrobial compounds
tested, resulting in logarithmic increases in susceptibility for three
compound classes (quinone analogues, furanocoumarins, and
arylmethanes). Second, at least six F420H2-dependent reductases
are capable of reducing antimicrobial compounds, including rep-
resentatives of the three above-mentioned compound classes.
Third, strains unable to utilize F420H2 were unable to reduce rep-
resentatives of these compounds and exhibited accelerated death.
On this basis, we propose thatmycobacteria employ some F420H2-
dependent reductases to reductively detoxify various antimicro-
bial compounds.
Environmental and pathogenic mycobacteria alike are re-
nowned for their intrinsic resistance to antimicrobial compounds.
Contributing to this capacity are their impermeable cell walls,
abundance of efflux pumps, and diversity of chemical detoxifica-
tion mechanisms (32). Mycobacteria produce a wide range of
characterized enzymes capable of degrading antimicrobial com-
pounds, including beta-lactamases (33), cytochrome P450 oxi-
dases (34), arylamine N-acetyltransferases (35), and nitroreduc-
tases (36). We propose that F420H2-dependent reductases of the
FDOR superfamily enhance this arsenal by reductively activating
organic compounds otherwise recalcitrant to biodegradation.
Such enzymes can reduce a wide range of functional groups (e.g.,
lactones, enones, and imines) in structurally diverse monocyclic
and polycyclic organic compounds by hydride transfer. It is pos-
sible to rationalize why some FDOR-reduced substrates are less
toxic to the cell based on the mode-of-action of the compounds:
reduction of quinones will prevent spontaneous formation of
semiquinone species that induce the production of reactive oxy-
gen species (ROS) (10, 37); reduction of the central carbon of
arylmethanes will produce nonplanar molecules unable to inter-
calate DNA (38); and reduction of furanocoumarins stimulates
hydrolytic ring opening that prevents binding to topoisomerase I
(16, 39). As with cytochrome P450 oxidases, however, the cellular
consequences of F420H2-dependent transformations will depend
on the compound reduced. While these enzymes will detoxify
antimicrobial compounds if the reduced compounds are less toxic
to the cell, as appears to be case for the furanocoumarins, quino-
nes, and arylmethanes tested, their effects will be null if oxidized
and reduced forms of the antimicrobial compound have similar
efficacy, as may be the case for clofazimine and rifampin. Further-
more, some F420H2-dependent reductases activate certain prod-
rugs, as reflected by the transformation of the clinical nitroimid-
azoles delamanid and pretomanid by the FDOR-A1 enzyme
Rv3547 (20, 30).
Natural selection for enzymatic strategies to reductively detox-
ify a wide range of antimicrobial natural productsmay explain the
number, diversity, and promiscuity of F420H2-dependent reduc-
tases found in mycobacteria. While the genus Mycobacterium is
renowned for its pathogens, the majority of its species are sapro-
phytic soil organisms, including its deepest-branching members
(40). We have demonstrated that FDORs can degrade fungal afla-
toxins (2) and plant furanocoumarins, as well as quinone groups,
which serve as building blocks for various streptomycete antibiot-
ics. Based on their chemical structures, other substrates poten-
tially compatible with FDORs include numerous natural products
of plant (e.g., flavonoids), bacterial (e.g., germicidins and mito-
mycins), and fungal (e.g., ochratoxins and patulin) origin. Our
recent evolutionary and structural analyses of the FDOR super-
family support the contention that the most numerous subclasses
of this family are also its most promiscuous. Whereas some phy-
logenetically clustered subgroups of this family appear to be func-
tionally constrained (e.g., B2 and B4 subgroups), the A1 and B1
enzymes have multiplied and diversified in function over the
course of mycobacterial evolution (5). Our structural analyses
have shown that enzymes from these subgroups have evolved
wide substrate-binding pockets, particularly the recently solved
MSMEG_2027 structure, which allow them to accommodate sub-
strates as structurally diverse as menadione, malachite green, and
methoxsalen (1, 2, 5). Docking studies have suggested that these
enzymes bind quinone and coumarin compounds through mul-
tiple hydrophobic interactions with their phenyl rings and stabi-
lizingTyr-mediated hydrogen-bonding interactionswith their ke-
tone groups (2, 5). Thus, by encoding multiple reductases with
broad specificities,mycobacteria increase the range of compounds
they can reductively detoxify.
In addition to facilitating direct detoxification mechanisms, it
is possible that F420 also enhances the capacity of mycobacteria to
resist antimicrobial agents through mechanisms independent of
detoxification. We found that the mutant strains unable to make
F420H2 were significantly more susceptible to quinolones and
first-line clinical antimycobacterials, even though they were not
substrates for the FDORs we tested. Other groups have similarly
shown that M. tuberculosis mutants unable to synthesize F420 are
hypersusceptible to isoniazid and moxifloxacin (10). It cannot be
ruled out that the numerous other F420H2-dependent reductases
of the FDOR and LLHT superfamilies metabolize such com-
pounds; this is possible in the cases of oxolinic acid and nalidixic
acid, which harbor compatible enone functionalities and cause
major growth inhibition. For the antimycobacterials, for which
more mild phenotypes were observed, it is more likely that more
general loss of functionality of F420-dependent oxidoreductases
results in pleiotropic effects on mycobacterial physiology that hy-
persensitize cells to antimicrobial stress. While the roles of this
cofactor in mycobacterial physiology remain incompletely de-
fined, F420 has been linked tomaintaining redox homeostasis (10),
maintaining cell wall structure (11), and generating antioxidants
(5). Disruption of any of these processes could result in broad
increases in antimicrobial susceptibility.
The findings from this work have wider environmental, med-
ical, and industrial significance. F420H2-dependent reductases ap-
pear to contribute to the antibiotic arms race through dual roles in
actinobacteria: whereas streptomycetes use such enzymes to syn-
thesize antibiotics (1, 8), mycobacteria harness them for detoxifi-
cation. This supports our recent hypothesis that F420 may signifi-
cantly shape the biological and chemical composition of soil
ecosystems (7). The results also have obvious clinical significance
given that FDORs have been retained in pathogenic mycobacteria
(1), and previous studies have shown that F420 is critical to anti-
microbial resistance of M. tuberculosis (1, 10, 13). However, there
is currently no evidence that F420H2-dependent reductases di-
rectly contribute to the detoxification of clinical antimycobacte-
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rial compounds. As recently reviewed (1), the substrate promis-
cuity of the F420H2-dependent reductase superfamily also opens
uppotential applications for these enzymes in bioremediation and
industrial biocatalysis; for example, FDORsmay be used to decol-
orize environmental toxins, such as malachite green (31), or cat-
alyze stereospecific imine reductions in asymmetric synthesis
(41). There is now need for further biochemical studies to fully
understand the basis and range of substrate promiscuity of
F420H2-dependent reductases, as well as targeted phenotypic stud-
ies of individual FDORs to better define their physiological and
pharmacological roles in mycobacteria.
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